Neumora Therapeutics Outlines 2026 Pipeline Strategy and Key Milestones

Neumora Therapeutics, Inc. (NASDAQ: NMRA), a clinical‑stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric and neurodegenerative diseases, has outlined its strategic priorities and anticipated milestones for 2026. The company emphasized multiple expected clinical data readouts and program advances that support its mission to redefine neuroscience drug development with treatments offering improved patient outcomes and quality of life. Key elements of the company’s 2026 plan include a joint topline data readout for its KOASTAL-2 and KOASTAL-3 Phase 3 studies of navacaprant in major depressive disorder in the second quarter, with a planned increase in enrollment for both trials. Neumora also intends to initiate a Phase 1 clinical program for NMRA‑215, a candidate for obesity treatment, in the first half of the year and expects to report weight‑loss results by late 2026. The company plans to advance its M4 Positive Allosteric Modulator (PAM) franchise — including NMRA‑898 and NMRA‑861 — and provide a comprehensive franchise update in mid‑2026. Already in January 2026, Neumora reported positive Phase 1b results from NMRA‑511, demonstrating a clinically meaningful effect on agitation associated with Alzheimer’s disease along with favorable tolerability. Financially, Neumora expects its existing cash and marketable securities to support operations into the third quarter of 2027, positioning it well to execute its 2026 pipeline strategy. #NeumoraTherapeutics #NeurosciencePipeline #ClinicalMilestones #BiotechNews #SlimScan #GrowthStocks #CANSLIM